NEW YORK, Feb 21 - Faced with growing concern from investors about prospects for future profitability, a number of genomics tool makers, large and small, have recently announced plans to refashion themselves as drug developers.

But Nathan Myhrvold, the revered software visionary turned biotechnology venture capitalist, on Wednesday warned genomics software and tool companies against rushing into the field of drug discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.